Abstract
IntroductionThe incidence of oesophageal adenocarcinoma (EA) has quadrupled in the last 30 years and outcomes remain poor. Unlike other epithelial cancers, targeted therapies for EA are at an early stage....
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have